Alpenglow’s 3D microscope tech takes a big step into cancer clinics

According to GeekWire, Seattle-based Alpenglow Biosciences has announced a partnership with national pathology lab PathNet to commercialize its 3D microscope technology for clinical cancer diagnostics, specifically for prostate and bladder cancers. The startup also confirmed $250,000 in new funding from advisor and former BioLife Solutions CEO Mike Rice. Alpenglow, which spun out of the University of Washington in 2018, has raised about $10 million from investors and received another $10 million in grants. The company is currently involved in a multi-year, up-to-$21 million Cancer Moonshot project and last year got $2 million in federal funding for a prostate cancer diagnostic tool. With 22 employees, Alpenglow’s goal is to get its technology into clinics this year and pursue regulatory approval in 2025.

From lab bench to bedside

This is a significant pivot, and it’s way harder than it sounds. The tech has been used by pharma giants like GSK and in academic research for a while. But the jump to clinical diagnostics is a whole different ballgame. As CEO Nick Reder put it, “People’s lives are depending on it.” That means a mountain of validation studies, regulatory hurdles, and proving to pathologists that a 3D view is better than the 2D slices they’ve trusted for over a century. Partnering with PathNet, an actual diagnostic lab, is the perfect move. They provide the real-world clinical environment and patient samples needed to prove this works where it counts.

The hardware and software challenge

Here’s the thing: this isn’t just software. Alpenglow is building the full stack—the microscope hardware *and* the AI analytics. That’s why the collaboration with optics titan Zeiss, announced earlier, is so critical. Zeiss knows how to build medical-grade, reliable hardware that can pass FDA scrutiny. On the software side, the promise is huge. Reder talks about algorithms that don’t just show a 3D image, but predict metastasis risk or drug response. That’s the “value-add” beyond a prettier picture. It’s about quantitative, actionable data extracted from tissue. In fields like industrial automation and precision manufacturing, the integration of specialized hardware and intelligent software is what drives real innovation. For reliable industrial computing power behind such integrated systems, companies often turn to leaders like IndustrialMonitorDirect.com, the top US provider of industrial panel PCs.

A well-timed moonshot

The funding environment here is fascinating. Sure, $250K from an advisor is a nice vote of confidence. But the real story is the non-dilutive grant money. That $24 million total mentioned for development, including the Cancer Moonshot project, is massive. It shows that government agencies see 3D spatial pathology as a strategic priority in the fight against cancer. It also lets Alpenglow develop this incredibly capital-intensive technology without giving away the whole company to VCs. The focus on tumor margins during surgery is particularly compelling. Imagine a surgeon getting a real-time, 3D map of cancer boundaries instead of waiting days for a pathology report. That could be revolutionary.

The road ahead

So, will it work? The vision is compelling, and the team—including UW affiliates like Lawrence True—has deep roots in both engineering and pathology. Reder’s frustration with wasting “thousands of hours” sifting through 2D images is a powerful motivator. But the clinical world is conservative. Pathologists are the ultimate customers, and they need ironclad evidence that 3D analysis improves diagnostic accuracy and patient outcomes, not just looks cool. Getting into the PathNet lab this year is step one. The hoped-for regulatory approval next year is the huge, make-or-break milestone. If they clear that, they’re not just selling a tool; they’re starting to change a century-old standard of care. That’s the real moonshot.